05/06/2026
News for investors and media. On Thursday the Supreme Court of the United States issued a unanimous decision favouring Hikma and effectively ending Amarin’s patent infringement litigation against the company. “Hikma has long fought for patients and their access to safe, high-quality, and affordable medicines,” said Sam Park, General Counsel, Hikma. “We welcome the United States Supreme Court’s decision, which allows us to continue providing millions of American patients with generic medicines that improve health and save lives.”
Read our press release: https://brnw.ch/21x36FD